TWI861354B - 抗klk5抗體 - Google Patents

抗klk5抗體 Download PDF

Info

Publication number
TWI861354B
TWI861354B TW110104069A TW110104069A TWI861354B TW I861354 B TWI861354 B TW I861354B TW 110104069 A TW110104069 A TW 110104069A TW 110104069 A TW110104069 A TW 110104069A TW I861354 B TWI861354 B TW I861354B
Authority
TW
Taiwan
Prior art keywords
seq
antibody
cdr
klk5
light chain
Prior art date
Application number
TW110104069A
Other languages
English (en)
Chinese (zh)
Other versions
TW202140569A (zh
Inventor
妮莎 達迪
彼得 查理斯 埃利奧特
塞普 弗蘭斯 羅曼 萊森
肖恩 梅森
大衛 詹姆士 麥克米蘭
吉莉安 克蕾兒 尼斯
妮科洛 彭戈
馬丁 安東尼 雷德
艾利森 透納
凱芮 路易斯 泰森
Original Assignee
比利時商Ｕｃｂ生物製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 比利時商Ｕｃｂ生物製藥公司 filed Critical 比利時商Ｕｃｂ生物製藥公司
Publication of TW202140569A publication Critical patent/TW202140569A/zh
Application granted granted Critical
Publication of TWI861354B publication Critical patent/TWI861354B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
TW110104069A 2020-02-03 2021-02-03 抗klk5抗體 TWI861354B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB2001447.8 2020-02-03
GBGB2001447.8A GB202001447D0 (en) 2020-02-03 2020-02-03 Antibodies

Publications (2)

Publication Number Publication Date
TW202140569A TW202140569A (zh) 2021-11-01
TWI861354B true TWI861354B (zh) 2024-11-11

Family

ID=69800047

Family Applications (2)

Application Number Title Priority Date Filing Date
TW110104069A TWI861354B (zh) 2020-02-03 2021-02-03 抗klk5抗體
TW110104070A TW202134276A (zh) 2020-02-03 2021-02-03 抗klk5之抗體

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW110104070A TW202134276A (zh) 2020-02-03 2021-02-03 抗klk5之抗體

Country Status (20)

Country Link
US (2) US20230070261A1 (https=)
EP (2) EP4100442A1 (https=)
JP (2) JP7837274B2 (https=)
KR (2) KR20220137669A (https=)
CN (2) CN115038722A (https=)
AR (2) AR121255A1 (https=)
AU (2) AU2021217523A1 (https=)
BR (2) BR112022015281A2 (https=)
CA (2) CA3169838A1 (https=)
CL (2) CL2022002079A1 (https=)
CO (2) CO2022012062A2 (https=)
EC (2) ECSP22060844A (https=)
GB (2) GB202001447D0 (https=)
IL (2) IL295247A (https=)
MX (2) MX2022009474A (https=)
PE (2) PE20221921A1 (https=)
PH (2) PH12022551962A1 (https=)
TW (2) TWI861354B (https=)
WO (2) WO2021156171A1 (https=)
ZA (2) ZA202208589B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022192647A1 (en) * 2021-03-12 2022-09-15 Genentech, Inc. Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019178316A1 (en) * 2018-03-14 2019-09-19 Genentech, Inc. Anti-klk5 antibodies and methods of use

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8927230D0 (en) * 1989-12-01 1990-01-31 Unilever Plc Reagents
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
PT1049787E (pt) 1998-01-23 2005-04-29 Vlaams Interuniv Inst Biotech Derivados de anticorpos multipropositos
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
WO2004041863A2 (en) * 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
ES2374068T3 (es) 2002-12-03 2012-02-13 Ucb Pharma, S.A. Ensayo para identificar células productoras de anticuerpos.
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
ES2551439T5 (es) 2003-07-01 2018-11-08 Ucb Biopharma Sprl Fragmentos Fab de anticuerpos modificados
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
NZ612578A (en) * 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
CA2646508A1 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
EP2535349A1 (en) 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
CA2737241C (en) 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB0920324D0 (en) 2009-11-19 2010-01-06 Ucb Pharma Sa Antibodies
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
WO2013068571A1 (en) 2011-11-11 2013-05-16 Ucb Pharma S.A. Albumin binding antibodies and binding fragments thereof
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
SI3097085T1 (sl) * 2014-01-23 2020-11-30 Sixera Pharma Ab Derivati benzoksazinona za zdravljenje kožnih bolezni
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
GB201411420D0 (en) 2014-06-26 2014-08-13 Ucb Biopharma Sprl Antibody constructs
CN108112254B (zh) * 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
EP3624820A1 (en) * 2017-04-21 2020-03-25 H. Hoffnabb-La Roche Ag Use of klk5 antagonists for treatment of a disease
GB201811368D0 (en) 2018-07-11 2018-08-29 Ucb Biopharma Sprl Antibody

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019178316A1 (en) * 2018-03-14 2019-09-19 Genentech, Inc. Anti-klk5 antibodies and methods of use

Also Published As

Publication number Publication date
PH12022551963A1 (en) 2023-10-09
EP4100442A1 (en) 2022-12-14
CO2022012062A2 (es) 2022-08-30
BR112022015281A2 (pt) 2022-09-20
IL295248A (en) 2022-10-01
CA3169838A1 (en) 2021-08-12
PE20221921A1 (es) 2022-12-29
US20230075753A1 (en) 2023-03-09
CN115052900A (zh) 2022-09-13
ZA202208589B (en) 2023-12-20
JP2023512304A (ja) 2023-03-24
US20230070261A1 (en) 2023-03-09
WO2021156170A1 (en) 2021-08-12
KR20220137669A (ko) 2022-10-12
AR121254A1 (es) 2022-05-04
ECSP22060844A (es) 2022-12-30
CA3169842A1 (en) 2021-08-12
CL2022002079A1 (es) 2023-01-06
PE20221922A1 (es) 2022-12-29
MX2022009474A (es) 2022-08-22
CO2022012061A2 (es) 2022-08-30
BR112022015279A2 (pt) 2022-09-20
IL295247A (en) 2022-10-01
WO2021156171A1 (en) 2021-08-12
ZA202208588B (en) 2023-12-20
AU2021217523A1 (en) 2022-09-01
TW202134276A (zh) 2021-09-16
MX2022009475A (es) 2022-08-22
ECSP22060834A (es) 2022-09-30
CN115038722A (zh) 2022-09-09
KR20220137668A (ko) 2022-10-12
JP7837274B2 (ja) 2026-03-30
CL2022002078A1 (es) 2023-01-06
GB202008022D0 (en) 2020-07-15
GB202001447D0 (en) 2020-03-18
JP7839093B2 (ja) 2026-04-01
EP4100441A1 (en) 2022-12-14
JP2023512320A (ja) 2023-03-24
TW202140569A (zh) 2021-11-01
PH12022551962A1 (en) 2023-10-09
AR121255A1 (es) 2022-05-04
AU2021216646A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
TWI806940B (zh) 抗體
US12545720B2 (en) Anti-alpha-synuclein antibodies
TWI861354B (zh) 抗klk5抗體
RU2847361C1 (ru) Антитела против klk5
HK40036532B (zh) 抗α突触核蛋白抗体
EA041378B1 (ru) Антитела к альфа-синуклеину